Brainstorm Cell Therapeutics Inc.

Equities

BCLI

US10501E2019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.5345 ^USD	+0.47%		+0.47%	+95.79%

Apr. 17	Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024	CI
Apr. 17	Brainstorm Cell Therapeutics Inc. Announces Management Changes	CI

US FDA panel votes against BrainStorm's ALS therapy

September 27, 2023 at 06:05 pm EDT

Sept 27 (Reuters) - The U.S. health regulator's advisers on Wednesday voted against BrainStorm Cell Therapeutics' therapy for patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli and Shounak Dasgupta)

Latest news about Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024	Apr. 16	CI
Brainstorm Cell Therapeutics Inc. Announces Management Changes	Apr. 16	CI
Brainstorm Cell Therapeutics Says FDA Agrees on Design of Phase 3B ALS Trial	Apr. 09	MT
Transcript : Brainstorm Cell Therapeutics Inc. - Special Call	Apr. 09
BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS	Apr. 09	CI
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
BrainStorm Cell Therapeutics Submits Special Protocol Assessment Request to FDA for Phase 3b Trial of NurOwn in ALS	Feb. 23	CI
Brainstorm Cell Therapeutics Shares Rise on Grants, Allowance of Patent Applications	Dec. 26	MT
Brainstorm Cell Therapeutics Inc. Announces Executive Changes	Dec. 20	CI
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS	Dec. 07	CI
Brainstorm Cell Says FDA Grants Meeting for Confirmatory Late-Stage Trial for NurOwn in Amyotrophic Lateral Sclerosis	Nov. 20	MT
Transcript : Brainstorm Cell Therapeutics Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Brainstorm Cell Therapeutics Inc. Announces Resignation of Dr. Kirk Taylor as EVP and Chief Medical Officer	23-10-24	CI
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS	23-10-24	CI
Transcript : Brainstorm Cell Therapeutics Inc. - Special Call	23-10-18
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	23-09-28	MT
Top Midday Decliners	23-09-28	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-09-28	MT
Maxim Downgrades Brainstorm Cell Therapeutics to Hold From Buy	23-09-28	MT
Wall Street Set to Open Flat; Q2 GDP Rises 2.1%; Jobless Claims Lower Than Expected	23-09-28	MT
Sector Update: Health Care Stocks Gain Premarket Thursday	23-09-28	MT
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket	23-09-28	MT
Top Premarket Decliners	23-09-28	MT

Chart Brainstorm Cell Therapeutics Inc.

Duration

Period

More charts

Company Profile

BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimerâs disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.5345 USD

Average target price

2.5 USD

Spread / Average Target

+367.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BRAINSTORM CELL THERAPEUTICS INC.	+95.79%	36.53M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research